Innoveren Scientific (IVRN) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36763
Entity Registrant Name	H-CYTE, INC
Entity Central Index Key	0001591165
Entity Tax Identification Number	46-3312262
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	201 East Kennedy Blvd
Entity Address, Address Line Two	Suite 425
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33602
City Area Code	(844)
Local Phone Number	633-6839
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HCYT
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		163,381,339

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash	$ 307,213	$ 1,640,645
Accounts receivable	9,200
Patient financing receivable, current portion	35,080
Other receivables	551	22,123
Prepaid expenses	106,228	94,434
Total Current Assets	458,272	1,757,202
Right-of-use asset	162,207	278,552
Property and equipment, net	40,344	139,175
Patient financing receivable, net of current portion	61,547
Other assets	18,412	29,239
Total assets	740,782	2,204,168
Current Liabilities
Accounts payable	1,044,727	1,006,968
Accrued liabilities	187,119	276,415
Other current liabilities	141,330	154,812
Notes payable, current portion	67,444	67,444
Convertible notes payable, related parties	1,584,665
Convertible notes payable	1,091,080
PPP Loan, current portion	105,878	606,811
Deferred revenue	410,031	634,149
Lease liability, current portion	92,589	139,189
Interest payable	4,385	6,898
Total Current Liabilities	4,729,248	2,892,686
Long-term Liabilities
Lease liability, net of current portion	87,304	157,050
PPP Loan, net of current portion		202,271
Total Long-term Liabilities	87,304	359,321
Total Liabilities	4,816,552	3,252,007
Stockholders’ Equity (Deficit)
Preferred Stock - $.001 par value: 1,000,000,000 shares authorized; Series A Preferred Stock - $.001 par value: 800,000,000 shares authorized, 515,874,354 and 538,109,409 shares issued and outstanding at September 30, 2021 and, December 31, 2020, respectively	515,874	538,109
Common stock - $.001 par value: 1,600,000,000 shares authorized, 149,394,519 and 127,159,464 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	149,394	127,159
Additional paid-in capital	43,540,358	42,515,999
Accumulated deficit	(47,911,264)	(43,858,974)
Non-controlling interest	(370,132)	(370,132)
Total Stockholders’ Deficit	(4,075,770)	(1,047,839)
Total Liabilities and Stockholders’ Deficit	$ 740,782	$ 2,204,168

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,600,000,000	1,600,000,000
Common stock, shares issued	149,394,519	127,159,464
Common stock, shares outstanding	149,394,519	127,159,464
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	800,000,000	800,000,000
Preferred stock, shares issued	515,874,354	538,109,409
Preferred stock, shares outstanding	515,874,354	538,109,409

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues	$ 460,216	$ 649,892	$ 1,286,841	$ 1,686,168
Cost of Sales	(138,786)	(161,252)	(553,454)	(608,079)
Gross Profit	321,430	488,640	733,387	1,078,089
Operating Expenses
Salaries and related costs	534,752	606,294	1,782,646	2,425,094
Share based compensation	162,359		1,024,359	643
Loss on disposal of property and equipment			92,804
Other general and administrative	789,365	542,317	2,229,120	2,806,707
Research and development	3,285	201,658	3,285	1,151,658
Advertising	58,643	51,643	223,871	222,196
Depreciation and amortization	300	30,095	13,859	69,447
Total Operating Expenses	1,548,704	1,432,007	5,369,944	6,675,745
Operating Loss	(1,227,274)	(943,367)	(4,636,557)	(5,597,656)
Other Income (Expense)
Forgiveness of PPP loan	698,820		698,820
Gain on extinguishment of debt				1,300,088
Interest expense	(50,516)	(1,039,349)	(110,446)	(1,458,521)
Other income (expense)	(7,641)	(34,504)	(4,107)	(25,182)
Change in fair value of redemption put liability		97,997		272,705
Loss on derivative instrument				(2,306,121)
Warrant modification expense				(70,851)
Change in fair value of derivative liability - warrants		5,869,102		2,986,853
Total Other Income (Expense)	640,663	4,893,246	584,267	698,971
Net Income (Loss)	(586,611)	3,949,879	(4,052,290)	(4,898,685)
Accrued dividends on outstanding Series B Convertible Preferred Stock		7,856		44,456
Deemed dividend on Series D Convertible Preferred Stock		36,450		277,719
Net Income (Loss) attributable to common stockholders	$ (586,611)	$ 3,905,573	$ (4,052,290)	$ (5,220,860)
Net Income (Loss) per share
Basic	$ 0	$ 0.03	$ (0.03)	$ (0.05)
Diluted	$ 0	$ 0.01	$ (0.03)	$ (0.05)
Weighted average outstanding shares - basic	142,407,798	116,970,322	140,074,271	106,691,185
Weighted average outstanding shares - diluted	142,407,798	664,244,972	140,074,271	106,691,185

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Series A Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2019		$ 6	$ 99,769	$ 28,172,145	$ (37,362,531)	$ (370,132)	$ (9,460,743)
Balance, shares at Dec. 31, 2019		6,100	99,768,704
Adjustment of exercise price on certain warrants				(438,913)			(438,913)
Reclassification of Series B warrants to equity				73,805			73,805
Reclassification of Series D warrants to equity				337,400			337,400
Conversion of Series B Preferred Stock		$ (6)	$ 2,120	150,983			153,097
Conversion of Series B Preferred Stock, shares		(6,100)	2,119,713
Conversion of Short-term related party convertible notes to Preferred Stock	$ 35,860			412,541			448,401
Conversion of Short-term related party convertible notes to Preferred Stock, shares	35,860,079
Issuance of Common Stock in connection with extinguishment of short term notes, related parties			$ 4,368	214,046			218,414
Issuance of Common Stock in connection with extinguishment of short term notes, related parties, shares			4,368,278
Deemed dividend on Series D Preferred Stock				(277,719)			(277,719)
Deemed dividend on Series D Preferred Stock at issuance					(37,207)		(37,207)
Issuance of Common Stock in exchange for consulting fees incurred			$ 109	34,891			35,000
Issuance of Common Stock in exchange for consulting fees incurred, shares			109,375
Issuance of warrants pursuant to private placement of Series D Convertible Preferred Stock				31,902			31,902
Conversion of short-term convertible notes to Preferred Stock	$ 287,984			4,751,484			5,039,468
Conversion of short-term convertible notes to Preferred Stock, shares	287,984,337
Issuance of warrants pursuant to extension of convertible short-term notes				17,636			17,636
Issuance of warrants pursuant to extension of maturity date on convertible debt				6,595			6,595
Conversion of related party warrants to equity				107,123			107,123
Conversion of Series D Preferred Stock to Common Stock			$ 15,773	6,422,441			6,438,214
Conversion of Series D Preferred Stock to Common Stock, shares			15,773,363
Issuance of Series A Preferred Stock in Rights Offering	$ 218,285			2,517,451			2,735,736
Issuance of Series A Preferred Stock in Rights Offering, shares	218,285,024
Share based compensation				643			643
Net loss					(4,898,685)		(4,898,685)
Balance at Sep. 30, 2020	$ 542,129		$ 122,139	42,489,998	(42,298,423)	(370,132)	485,711
Balance, shares at Sep. 30, 2020	542,129,440		122,139,433
Accrued dividends on Series B Preferred Stock				(44,456)			(44,456)
Balance at Jun. 30, 2020		$ 6	$ 104,246	27,761,076	(46,248,302)	(370,132)	(18,753,106)
Balance, shares at Jun. 30, 2020		6,100	104,246,357
Conversion of Series B Preferred Stock to Common Stock		$ (6)	$ 2,120	150,983			153,097
Conversion of series B preferred stock to common stock, shares		(6,100)	2,119,713
Accrued dividends on Series B Preferred Stock				(7,856)			(7,856)
Deemed dividend on Series D Preferred Stock				(36,450)			(36,450)
Conversion of short-term convertible notes to Preferred Stock	$ 287,984			4,751,484			5,039,468
Conversion of short-term convertible notes to Preferred Stock, shares	287,984,337
Conversion of related party warrants to equity				107,123			107,123
Conversion of Series D Preferred Stock to Common Stock			$ 15,773	6,422,441			6,438,214
Conversion of Series D Preferred Stock to Common Stock, shares			15,773,363
Reclassification of Series B warrants to Common Stock				73,805			73,805
Reclassification of Series D warrants to Common Stock				337,400			337,400
Issuance of Series A Preferred Stock in Rights Offering	$ 218,285			2,517,451			2,735,736
Issuance of Series A Preferred Stock in Rights Offering, shares	218,285,024
Conversion of Short-term related party convertible notes to Preferred Stock	$ 35,860			412,541			448,401
Conversion of Short-term related party convertible notes to Preferred Stock, shares	35,860,079
Net loss					3,949,879		3,949,879
Balance at Sep. 30, 2020	$ 542,129		$ 122,139	42,489,998	(42,298,423)	(370,132)	485,711
Balance, shares at Sep. 30, 2020	542,129,440		122,139,433
Balance at Dec. 31, 2020	$ 538,109		$ 127,159	42,515,999	(43,858,974)	(370,132)	(1,047,839)
Balance, shares at Dec. 31, 2020	538,109,409		127,159,464
Share based compensation				1,024,359			1,024,359
Conversion of Series A Preferred Stock to common stock	$ (22,235)		$ 22,235
Conversion of Series A Preferred Stock to common stock, shares	(22,235,055)		22,235,055
Net loss					(4,052,290)		(4,052,290)
Balance at Sep. 30, 2021	$ 515,874		$ 149,394	43,540,358	(47,911,264)	(370,132)	(4,075,770)
Balance, shares at Sep. 30, 2021	515,874,354		149,394,519
Balance at Jun. 30, 2021	$ 520,305		$ 144,963	43,377,999	(47,324,653)	(370,132)	(3,651,518)
Balance, shares at Jun. 30, 2021	520,305,884		144,962,989
Share based compensation				162,359			162,359
Conversion of Series A Preferred Stock to common stock	$ (4,431)		$ 4,431
Conversion of Series A Preferred Stock to common stock, shares	(4,431,530)		4,431,530
Net loss					(586,611)		(586,611)
Balance at Sep. 30, 2021	$ 515,874		$ 149,394	$ 43,540,358	$ (47,911,264)	$ (370,132)	$ (4,075,770)
Balance, shares at Sep. 30, 2021	515,874,354		149,394,519

Condensed Consolidated Statemen

Condensed Consolidated Statement of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities
Net loss	$ (4,052,290)	$ (4,898,685)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,859	69,447
Amortization of debt discount		1,395,007
Forgiveness of PPP loan	(698,820)
Issuance of warrants to extend convertible debt		17,636
Issuance of warrants pursuant to short-term notes, related party		(1,300,088)
Issuance of warrants to extend short-term debt		6,595
Share based compensation expense	1,024,359	643
Common stock issued for consulting services		35,000
Change in fair value of derivative liability - warrants		(2,986,853)
Change in fair value of derivative liability - warrants		(272,705)
Change in fair value of derivative liability - Day one derivative loss		2,306,121
Warrant modification expense		70,851
Loss on disposal of property and equipment	92,804
Changes in operating assets and liabilities:
Accounts receivable	(9,200)	20,167
Patient financing receivable, current portion	(35,080)
Other receivables	21,572	16,372
Patient financing receivable, net of current portion	(61,547)
Prepaid expenses and other assets	(968)	707,457
Interest payable	6,333	35,565
Accounts Payable	37,759	(237,409)
Accrued liabilities	(89,296)	(21,206)
Other current liabilities	(13,482)	(15,680)
Deferred revenue	(224,118)	(409,375)
Net Cash Used in Operating Activities	(3,988,115)	(5,461,140)
Cash Flows from Investing Activities
Purchase of property and equipment	(7,832)	(2,285)
Net Cash Used in Investing Activities	(7,832)	(2,285)
Cash Flows from Financing Activities
Proceeds from convertible notes payable, related parties	1,584,665
Proceeds from convertible notes payable	1,091,080
Proceeds from PPP loan		809,082
Payments on PPP Loan	(13,230)	(10,937)
Proceeds from warrants, net of issuance costs		3,842,695
Proceeds from issuance of Preferred Stock Series A, net of issuance costs		2,735,736
Proceeds from issuance of Series D Convertible Preferred Stock		100,000
Net Cash Provided by Financing Activities	2,662,515	7,476,576
Net Change in Cash	(1,333,432)	2,013,151
Cash - Beginning of period	1,640,645	1,424,096
Cash - End of period	307,213	3,437,247
Supplementary Cash Flow Information
Cash paid for interest	3,367	17,066
Non-cash investing and financing activities
Deemed Dividend on Series D Convertible Preferred Stock		314,926
Conversion of Series D Preferred Stock to Common Stock		6,438,214
Conversion of related party (Horne) warrants to equity		107,123
Reclassification of Series B warrants to equity		73,805
Reclassification of Series D warrants to equity		337,400
Issuance of Common Stock in exchange for consulting fees		35,000
Issuance of warrants to extend short-term debt		6,595
Issuance of warrants pursuant to extension of convertible short-term notes		17,636
Conversion of Series B Preferred Stock to Common Stock		153,097
Conversion of short-term related party convertible notes to Preferred Stock		412,541
Conversion of short-term convertible notes to Preferred Stock		4,751,484
Dividends accrued on Series B Preferred Stock		44,456
Adjustment of exercise price on convertible debt		438,913
Issuance of Common Stock in connection with extinguishment of short-term notes, related parties		218,414
Issuance of Warrants in connection with Series D Convertible Preferred Stock		$ 31,902

Description of the Company

Description of the Company	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Description of the Company	Note 1 - Description of the Company H-CYTE, Inc (“the Company”) is a hybrid-biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. During the last two years, the Company has evolved into two separate divisions with its entrance into the biologics development space (“Biologics Division”). This new division is complementary to the Company’s current Lung Health Institute (LHI) autologous infusion therapy business (“Infusion Division”) and is focused on underserved disease states. On September 8, 2021, the Company announced that its Lung Health Institute facilities changed its name to Centers for Respiratory Health as the clinics continue to deliver treatments for patients with chronic respiratory and pulmonary disorders. The consolidated results for H-CYTE include the following wholly-owned subsidiaries: H-CYTE Management, LLC, Medovex Corp, Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC and the results include Lung Institute Dallas, PLLC (“LI Dallas”), Lung Institute Nashville, PLLC (“LI Nashville”), Lung Institute Pittsburgh, PLLC (“LI Pittsburgh”), and Lung Institute Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). Additionally, H-CYTE Management, LLC is the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale. The LI Dallas and LI Pittsburgh clinics did not reopen in 2020 after the temporary closure of all LI clinics due to COVID-19. These two clinics will remain permanently closed. On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC”) gained control of the Company by subsequently owning approximately 61 Autologous Infusion Therapy (“Infusion Division”) The Infusion Division develops and implements innovative treatment options in autologous cellular therapy (PRP-PBMC) to treat chronic lung disorders. Committed to an individualized patient-centric approach, this division provides oversight and management of the highest quality to the LHI clinics, while producing positive medical outcomes following the strictest Centers for Disease Control and Prevention (the “CDC”) guidelines. Biotech Development (“Biologics Division”) On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post U.S. Food & Drug Administration, the “FDA”, approval) a biologic combining its PRP-PBMC technology with Rion’s exosomes (“EV”) technology for the treatment of chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel EV technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular, and neurological organ systems. This agreement provides for a 10 -year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop combined proprietary biologics. The Company is evaluating alternate EV technologies to determine the most favorable path forward. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion has completed the research and development work which is under review by the Company. The Company is assessing if the Rion combined proprietary biologic is a more viable solution than potentially progressing with a single entity biologic from an alternative commercial source. On April 2, 2021, the Company entered into a series of agreements with Medovex, LLC to pursue a joint venture regarding the continued development and commercialization of the DenerveX device for business outside of the U.S. The Company has determined that the transactions resulting from the series of agreements with Medovex, LLC are immaterial. The Company will assess the progress of the joint venture on a quarterly basis for materiality.

Basis of presentation

Basis of presentation	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of presentation	Note 2 – Basis of presentation The accompanying interim consolidated financial statements have been prepared based upon U.S. Securities and Exchange Commission rules that permit reduced disclosure for interim periods. Therefore, they do not include all information and footnote disclosures necessary for a complete presentation of the Company’s financial position, results of operations, and cash flows in conformity with generally accepted accounting principles. The Company filed audited consolidated financial statements as of and for the fiscal years ended December 31, 2020 and 2019, which included all information and notes necessary for such complete presentation in conjunction with its 2020 Annual Report on Form 10-K. The results of operations for the interim period ended September 30, 2021 are not necessarily indicative of the results to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020, which are contained in the Company’s 2020 Annual Report on Form 10-K. For further discussion refer to Note 2 – “Basis Of Presentation And Summary of Significant Accounting Policies” to the consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations–Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management’s Plans	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management’s Plans	Note 3 - Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $ 587 ,000 and $ 4,052 ,000 for the three and nine months ended September 30, 2021. The Company has historically incurred losses from operations and expects to continue to generate negative cash flows as it implements its plan around the Biosciences Division. The interim consolidated financial statements are prepared using accounting principles generally accepted in the United States (“U.S. GAAP”) as applicable to a going concern. COVID-19 has adversely affected the Company’s financial condition and results of operations. The impact of the outbreak of COVID-19 on the economy in the U.S. and the rest of the world is expected to continue to be significant. The extent to which the COVID-19 outbreak will continue to impact the economy is highly uncertain and cannot be predicted. Accordingly, the Company cannot predict the extent to which its financial condition and results of operations will be affected. Convertible Notes Payable On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $ 2,575,000 maturing on March 31, 2022 with an annual interest rate of 8 %. The Notes, plus accrued interest, are convertible into shares of Common Stock at a discount of 20 % to the price paid for such New Securities in the next round of financing that meets the definition of Qualified Financing as defined in the April 2021 Note Purchase Agreement. The Notes are secured by the assets of the Company under a security agreement with the Holders. The lead investor of the April 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $ 1,500,000 of the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which is a principal stockholder and related party of the Company. An additional affiliate of FWHC, LLC provided an additional $ 25,000 as part of the April 2021 Note Purchase Agreement. On October 14, 2021, H-Cyte, Inc. (the “Company”) entered into the Second Closing Bring Down Agreement (the “October 2021 Note Purchase Agreement”) whereby the five (5) investors who had entered into the April 2021 Note Purchase Agreement purchased new notes in the Company in the aggregate principal amount of $ 750,000 . The Notes are due and payable on March 31, 2022 and bear interest at an annual rate of 8 %. The Notes are convertible into shares of Common Stock at a discount of 20 % to the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the April 2021 Note Purchase Agreement. The Notes are secured by all of the assets of the Company under a security agreement with the Holders. The lead investor of the October 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $ 437,000 of the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which is a principal stockholder and related party of the Company. An additional affiliate of FWHC, LLC provided an additional $ 7,500 as part of the October 2021 Note Purchase Agreement. The Company chose early adoption of ASU 2020-06 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The Company had cash on hand of approximately $ 307,000 as of September 30, 2021 and approximately $ 644,000 as of November 9, 2021. The Company’s cash is insufficient to fund its operations over the next year and the Company is currently working to obtain additional debt or equity financing to help support the Biosciences Division’s business model. There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to discontinue operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Right-of-use Asset And Lease Li

Right-of-use Asset And Lease Liability	9 Months Ended
	Sep. 30, 2021
Right-of-use Asset And Lease Liability
Right-of-use Asset And Lease Liability	Note 4 – Right-of-use Asset And Lease Liability The components of lease expense, which are included in other general and administrative expense, for the three and nine months ended September 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating lease expense $ 69,582 140,381 253,233 442,409 Cash paid for amounts included in the measurement of lease liabilities for the three and nine months ended September 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating cash flows from operating leases $ 69,582 140,381 253,233 442,409 Supplemental balance sheet and other information related to operating leases are as follows: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION September 30, 2021 December 31, 2020 Operating leases right-of-use assets $ 162,207 278,552 Lease liability, current portion 92,589 139,189 Lease liability, net of current portion 87,304 157,050 Total operating lease liabilities $ 179,893 296,239 Weighted average remaining lease term 1.92 2.32 Weighted average discount rate 9.96 % 10.31 % Future maturities of operating lease liabilities as of September 30, 2021 are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Operating leases Remainder of 2021 $ 25,584 2022 102,891 2023 69,333 Total lease payments 197,808 Total lease payments 197,808 Less: Interest 17,915 Total lease liability $ 179,893 The Company did not renew its corporate office space lease in Tampa, FL which expired on March 31, 2021. The Company leases medical clinic space in Tampa, FL, Nashville, TN, and Scottsdale, AZ. These clinic locations have various expiration dates through August 31, 2023. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. The Company entered into a twelve-month lease extension for its Tampa location beginning April 1, 2021 totaling $ 71,775 94,500

Property And Equipment

Property And Equipment	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property And Equipment	Note 5 - Property And Equipment Property and equipment, net, consists of the following: SCHEDULE OF PROPERTY AND EQUIPMENT Useful Life September 30, 2021 December 31, 2020 Furniture and fixtures 5 7 $ 96,185 $ 231,222 Computers and software 3 7 213,660 246,323 Leasehold improvements 15 40,130 155,583 Property and equipment 349,975 633,128 Less: accumulated depreciation (309,631 ) (493,953 ) Total $ 40,344 $ 139,175 Depreciation expense was approximately $ 300 and $ 14,000 for the three and nine months ended September 30, 2021, respectively. Depreciation expense was approximately $ 30,000 and $ 69,000 for the three and nine months ended September 30, 2020, respectively. The Company uses the straight-line depreciation method to calculate depreciation expense. The Company recorded a loss on disposal of approximately $ 0 93,000 for the three and nine months ended September 30, 2021, respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions Board Members and Officers and Related Expenses Effective February 1, 2019, the Company entered into an oral consulting agreement with Mr. Raymond Monteleone, Board Member and Chairman of the Audit Committee in which Mr. Monteleone received $ 10,000 per month for advisory services and $ 5,000 per quarter as Audit Committee Chair in addition to regular quarterly board meeting fees. Effective March 25, 2020, the Company reduced the advisory services to $ 5,000 per month and the fees per quarter as the Audit Committee Chair to $ 2,500 per quarter. On January 12, 2021, Mr. Monteleone was appointed as Chairman of the Board and Compensation Committee Chair. There are understandings between the Company and Mr. Monteleone for him to receive $ 5,000 2,500 18,000 and $ 53,000 in compensation to Mr. Monteleone for the three and nine months ended September 30, 2021, respectively. The Company expensed approximately $ 18,000 and $ 65,000 in compensation to Mr. Monteleone for the three and nine months ended September 30, 2020, respectively. Effective October 1, 2020, the Company entered into an oral agreement with Mr. Michael Yurkowsky in which Mr. Yurkowsky will receive $ 4,167 per month to serve on the Board of Directors. The Company expensed approximately $ 13,000 and $ 38,000 in compensation to Mr. Yurkowsky for the three and nine months ended September 30, 2021, respectively. For the three and nine months ended September 30, 2020, the Company expensed $ 0 . On January 12, 2021, Mr. William Horne stepped down as Chairman of the Board. Mr. Horne will remain a member of the Board. Effective March 1, 2021, the Company entered into an oral agreement with Mr. Horne in which Mr. Horne will receive $ 4,167 per month to serve on the Board of Directors. The Company expensed approximately $ 13,000 and $ 29,000 in Board fee compensation to Mr. Horne for the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2020, the Company expensed $ 0 . Debt and Other Obligations The convertible notes payable and convertible notes payable, related parties are detailed in Note 3 - “Liquidity, Going Concern and Management’s Plans” in this Form 10-Q. Change in Control On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC”) gained control of the Company by subsequently owning approximately 61 15,518,111 123,031,819 75,162,429 35,860,079 117,362,143 273,356,676 10 0.014 Convertible Notes Payable On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $ 2,575,000 March 31, 2022 8 20 1,500,000 25,000 On October 14, 2021, H-Cyte, Inc. (the “Company”) entered into the Second Closing Bring Down Agreement (the “October 2021 Note Purchase Agreement”) whereby the five (5) investors who had entered into the April 2021 Note Purchase Agreement purchased new notes in the Company in the aggregate principal amount of $ 750,000 . The Notes are due and payable on March 31, 2022 and bear interest at an annual rate of 8 %. The Notes are convertible into shares of Common Stock at a discount of 20 % to the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the Note Purchase Agreement. The Notes are secured by all of the assets of the Company under a security agreement with the Holders. The lead investor of the October 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $ 437,000 of the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which is a principal stockholder and related party of the Company. An additional affiliate of FWHC, LLC provided an additional $ 7,500 as part of the October 2021 Note Purchase Agreement.

Equity Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Equity Transactions	Note 7 - Equity Transactions Common Stock Issuance In February 2020, the Company issued LilyCon Investments $ 35,000 0.32 109,375 On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 ten 0.014 On July 28, 2020, the Company issued an aggregate of 17,893,076 On July 29, 2020, the Company filed its Second Amended and Restated Certificate of Incorporation (the “Amended COI”). The Amended COI provides for the issuance of up to 1,600,000,000 1,000,000,000 800,000,000 Series A Preferred Stock On September 11, 2020, the registered Rights Offering (Registration No. 333-239629) of the Company expired. Pursuant to the Rights Offering, on September 24, 2020, the Company issued (i) 15,235,381 0.014 203,049,643 3,055,985 Additionally, on September 24, 2020, the Company issued an aggregate of 323,844,416 4,483,617 During the three and nine months ended September 30, 2021, 4,431,530 and 22,235,055 shares of Series A Preferred Stock were converted to Common Stock at the request of certain Series A Preferred Shareholders. Voting Rights Holders of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock and to vote upon any matter submitted to a vote of the holders of common stock. Each Series A Holder shall vote on each matter on an as converted basis submitted to them with the holders of common stock. Conversion Series A Preferred Stock converts to common stock at a 1:1 ratio Liquidation Series A Preferred Stock does not have preferential treatment over common stock shareholders if the Company liquidates or dissolves. Share-Based Compensation The Company utilizes the Black-Scholes valuation method to recognize share-based compensation expense over the vesting period. The expected life represents the period that the stock-based compensation awards are expected to be outstanding. Stock Option Activity On April 1, 2021, the Board of Directors of the Company approved and granted to certain directors and officers of the Company an aggregate of 54,750,000 4,750,000 0.07 ten years The Board of Directors decided not to renew the former CEO’s (Robert Greif) employment contract; therefore, the unvested shares were forfeited resulting in a reduction of share-based compensation of approximately $ 205,000 For the nine months ended September 30, 2020, all outstanding stock options were fully vested, and related compensation expense recognized. For the nine months ended September 30, 2021, 29,635,000 options were outstanding and 14,801,667 were vested. For the three and nine months ended September 30, 2021 the Company recognized approximately $ 162,000 and $ 1,024,000 in stock-based compensation expense, respectively. The Company has approximately $ 574,000 of unrecognized compensation costs related to non-vested stock options, which is expected to be recognized over a weighted average period of approximately 3.12 years. Inputs used in the valuation models are as follows: SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS 2021 Grants Option value $ 0.054 to 0.056 Risk Free Rate 0.90 % to 1.37 % Expected Dividend- yield - to - Expected Volatility 173.99 % to 176.04 % Expected term (years) 5 to 7 The following is a summary of stock option activity for the nine months ended September 30, 2020 and 2021: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted - - - Expired/Cancelled (15,000 ) 1.35 - Outstanding and exercisable at September 30, 2020 410,000 $ 1.39 7.23 Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted 54,750,000 0.07 9.50 Expired/Cancelled (25,525,000 ) 0.07 - Outstanding at September 30, 2021 29,635,000 $ 0.10 9.41 Exercisable at September 30, 2021 14,801,667 $ 0.10 9.41 The following is a summary of the Company’s non-vested shares for the nine months ended September 30, 2021: SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED Shares Weighted Non-vested at December 31, 2020 - - Granted 54,750,000 0.03 Vested (14,416,667 ) 0.05 Forfeited (25,500,000 ) 0.07 Non-vested at September 30, 2021 14,833,333 0.11 Non-Controlling Interest For the nine months ended September 30, 2021 and 2020, the Company consolidated the results for LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale as VIEs. The Company owns no portion of any of these four entities, however, the Company maintains control through their management role for each of the clinics, in accordance with each clinic’s respective management services agreement. Based on these agreements, the Company has the responsibility to run and make decisions on behalf of the clinics, except for medical care and procedures. Beginning in January 2018, the Company adopted the policy, for all of the VIEs, that the management fee charged by the Company would equal the amount of net income from each VIE on a monthly basis, bringing the amount of the net income to $0 each month for the VIEs. Due to this change in policy, there was no change in the non-controlling interest for the nine months ended September 30, 2021 or 2020 related to the net income (loss) as it was $ 0 Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses. The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE 2021 2020 For the Nine Months Ended September 30, 2021 2020 Warrants to purchase common stock (in the money) 385,033,082 367,515,043 Series A Preferred Stock convertible to common stock 515,874,354 542,129,440 Total 900,907,436 909,644,483 Excluded from the above table are 22,607,701 warrants and 29,635,000 stock options for the nine months ended September 30, 2021 as they are out of the money (exercise price greater than $ 0.04 ). Inclusion of such would be anti-dilutive.

Commitments & Contingencies

Commitments & Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 8 – Commitments & Contingencies Litigation From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect the Company’s financial condition, results of operations, and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention, and other factors. The Company expenses legal costs in the period incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against the Company in the future, and these matters could relate to prior, current, or future transactions or events. As of September 30, 2021, the Company had no litigation matters which required any accrual or disclosure. Rion Agreements On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post FDA approval) a biologic for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel biologics technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular and neurological organ systems. This agreement provides for a 10-year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop proprietary biologics. The Company is currently evaluating the potential of a combined biologic and the utilization of this agreement. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion also agrees to consult with H-CYTE in its arrangement for services from third parties unaffiliated with Rion to support research, development, regulatory approval, and commercialization of the biologic. For the three and nine months ended September 30, 2021 the Company expensed $ 0 . For the three and nine months ended September 30, 2020 the Company expensed $ 202,000 and $ 1,152,000 The Company is currently evaluating the potential of a combined biologic and the utilization of this agreement.

Short-term Debt

Short-term Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Short-term Debt	Note 9 – Short-term Debt Convertible Notes Payable Convertible Notes payable represents a securities purchase agreement with select accredited investors, which was assumed in the Asset Purchase Agreement between Medovex Corp and Regenerative Medicine Solutions, LLC (“Merger”) in 2019 (see Note 1 – “Description of the Company” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). The debt assumed by the Company, as part of the merger, consisted of $ 750,000 50,000 Each Unit consists of (i) a 12 0.001 0.40 three In 2019, $ 100,000 of the Convertible Notes were converted into shares of common stock, and $ 350,000 of the Convertible Notes were redeemed by the Company. The Company reached an extension with the remaining noteholder which extended the maturity date of the Hawes Notes for one year, until September 30, 2020. The notes had a principal balance of $ 300,000 plus penalties of approximately $ 85,000 and accrued interest of approximately $ 40,000 for a total adjusted principal balance upon renewal of $ 424,615 as of March 31, 2020. In connection with the April Offering, the Company entered into an amendment with the Investor with respect to the outstanding 12% Senior Secured Convertible Note due September 30, 2020, which was originally issued in 2018 and assumed in the Merger and which was purchased by the Investor from its original holder, George Hawes, on March 27, 2020 (see Note 11 –“Debt” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $ 2,575,000 March 31, 2022 8 20 1,500,000 25,000 Interest expense is being accreted to the principal balance using the effective interest method. For the three months and nine months ended September 30, 2021, the Company recorded interest expense of $ 30,445 20,962 59,665 41,080 Notes Payable Notes payable were assumed in the Merger and are due in aggregate monthly installments of approximately $ 5,800 and carry an interest rate of 5 %. Each note originally had a maturity date of August 1, 2019 . The Company finalized an eighteen-month extension to March 1, 2021. The Company is working with the lender for an additional extension of the promissory notes. The promissory notes have an aggregate outstanding balance of approximately $ 67,000 at September 30, 2021 and December 31, 2020. The Company has not made payments on this note since February 10, 2020, due to COVID-19, resulting in accrued interest of approximately $ 5,000 . On March 27, 2020, the Company issued a demand note in the principal amount of $ 500,000 500,000 1,000,000 Paycheck Protection Program On April 29, 2020, the Company issued a promissory note in the principal amount of $ 809,082 The Company could apply for loan forgiveness in an amount equal to the sum of the following costs incurred by the Company: 1) payroll costs; 2) any payment of interest on covered mortgage obligations; 3) any payment on a covered rent obligation; and 4) any covered utility payment The Company received notification from the Small Business Administration (“SBA”), dated August 17, 2021, notifying it that $ 689,974 in principal and $ 8,847 in interest was forgiven under the guidelines of the Paycheck Protection Program. As of September 30, 2021, the current balance is $ 105,878 with $ 405 in interest payable.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Note 10 – Derivative Liabilities The Company’s derivative liabilities are classified within Level 3 of the fair value hierarchy because certain unobservable inputs were used in the valuation models. These assumptions included estimated future stock prices, potential down-round financings for the Warrants, and potential redemptions for the Redemption Put Liability. The following are rollforwards of the liabilities during the nine months ended September 30, 2020: SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS Derivative Liability - Warrants Balance at December 31, 2019 $ 315,855 Series D Warrant reclass from equity to liability classification 509,762 Warrants issued with modification of Horne Note 198,994 Warrants issued with April 17, 2020 financing 6,148,816 Fair value adjustments (2,986,853 ) Warrant reclassification from liability to equity classification (4,186,574 ) Balance at September 30, 2020 $ — Redemption Put Liability Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,306 Fair value adjustments (272,705 ) Balance at September 30, 2020 $ — (1) The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of September 30, 2020. (2) Upon the closing of a Qualified Financing on September 11, 2020, the Derivative Liability- Warrants were reclassed to stockholder’s equity. (3) The Series D Preferred Stock was converted into common stock on July 28, 2020 at which time the Derivative Put Liability was no longer applicable, and its fair value as adjusted to zero and the extinguishment was recorded to income. Derivative Liability- Warrants Series B Warrants As part of the April 2020 Offering, the holders of the Series B Warrants agreed to terminate anti-dilution price protection in their warrants and adjusted the exercise price to equal the price per share at which shares of preferred stock are offered for purchase in a Qualified Financing. The modification resulted in an increase of approximately $ 75,000 to the fair value of the derivative liability related to the Series B Warrants. In addition, the Company recorded a change in fair market value of approximately $ 317,000 to the fair value of the derivative liability before the reclass to equity. Upon the closing of a Qualified Financing, which occurred on September 11, 2020, the exercise price of the Series B Warrants became fixed at $ 0.014 0.027 0.014 260 0.13 1.33 73,805 Series D Warrants In conjunction with the Series D Preferred Financing, the Company originally issued Series D warrants to purchase 14,669,757 shares of Common Stock with an exercise price of $ 0.75 per share. At inception, the Series D warrants met all the criteria to be classified as equity. As part of the April 2020 Offering, the exercise price of the Series D Warrants was reduced to the price per share at which shares of preferred stock are offered for purchase in a Qualified Financing. The modification of the exercise price resulted in the warrants requiring liability classification. The Series D Warrants were measured at fair value before and after the modification, resulting in a fair market value of approximately $ 510,000 when the warrants were reclassified to a liability on July 28, 2020. Upon the closing of a Qualified Financing, which occurred on September 11, 2020, the exercise price of the Series D Warrants became fixed at $ 0.014 0.027 0.014 111 0.67 9.2 337,400 Horne Warrants On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 ten 0.05 0.014 101 0.65 199,000 Upon the closing of a Qualified Financing, which occurred on September 11, 2020, the exercise price of the Series D Warrants became fixed at $ 0.014 0.027 0.014 103 0.67 10 107,123 April Bridge Loan and Converted Advance Warrants The April 2020 Offering entitled the investors to warrants with the right to purchase up to 100% of the aggregate number of shares of Common Stock into which the Purchaser’s Note may ultimately be converted. The Company also received a $1,000,000 advance which was converted into a Converted Advance Note and Converted Advance Warrants in April 2020. The Converted Advance Warrants entitle the holder to purchase up to 200% of the aggregate number of shares of Common Stock into which the Converted Advanced Note may ultimately be converted. The Company received an aggregate of $ 2,842,695 1,000,000 0.014 203,050,000 142,857,000 0.05 0.014 103 0.65 10 years 3,279,000 2,869,000 6,149,000 Upon the closing of a Qualified Financing, which occurred on September 11, 2020, the exercise price of the Purchaser and Converted Advance Warrants became fixed at $0.014 and the Company then had sufficient authorized and unissued shares available to satisfy all their commitments under their equity-linked contracts. There are 212,821,929 150,324,857 0.027 0.014 106 0.67 10 3,668,247 When the Company entered into the April Offering and revised the exercise price of their warrants to the price per share at which shares of preferred stock are offered for purchase in a Qualified Financing, they no longer had sufficient authorized and unissued shares available to satisfy all their commitments to issue shares under their equity-linked contracts. The Company adopted the sequencing approach based on the earliest issuance date. Therefore, warrants issued before the April Offering did not require liability classification, while Warrants issued with the April financing, or subsequently, were classified as liabilities until such time the Company had sufficient authorized shares. At December 31, 2019, due to the down round provision contained in the warrants, which could provide for the issuance of additional warrant shares as well as a reduction in the exercise price, the model also considered subjective assumptions related to the shares that would be issued in a down-round financing and the potential adjustment to the exercise price. On April 17, 2020, the holders of the warrants agreed to terminate all anti-dilution price protections in their warrants. The derivative liability has been remeasured to fair value at the end of each reporting period and the change in fair value, of approximately $ 5,869,102 2,986,853 The fair value of the derivative liability included on the consolidated balance sheet was approximately $ 0 316,000 In conjunction with the Series D Preferred financing (See Note 12), the Company offered the Series B warrant holders the option to exchange their warrants on the basis of 1 warrant for 0.40 common shares. 1,007,813 75,000 403,125 73,000 Redemption Put Liability As described in Note 12, the redemption put provision embedded in the Series D financing required bifurcation and measurement at fair value as a derivative. If the redemption put provision is triggered, it allows either payment in cash or the issuance of “Trigger Event Warrants”. Accordingly, the fair value of the Redemption put liability considered management’s estimate of the probability of cash payment versus payment in Trigger Event Warrants and was valued using a Monte Carlo Simulation which uses randomly generated stock-price paths obtained through a Geometric Brownian Motion stock price simulation. The fair value of the redemption provision was significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the redemption factor. On July 28, 2020, the Series D Preferred Stock was converted into Common Stock, at which time the redemption put was no longer applicable and the fair value of the redemption put was adjusted to zero. The fair market value of the redemption put liability at inception was approximately $ 614,000 which was recorded as a liability and remeasured to fair value at the end of each reporting period. The change in fair value of approximately $ 98,000 and $ 273,000 has been recorded as a component of other income (expense) in the Company’s consolidated statement of operations for the three and nine months ended September 30, 2020, respectively. The fair value of the redemption put liability included on the consolidated balance sheet was approximately $ 0 and $ 267,000 as of September 30, 2020 and December 31, 2019, respectively. The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of December 31, 2020 (see Note 12- “Derivative Liability-Warrants and Redemption Put” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K).

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2021
Common Stock Warrants
Common Stock Warrants	Note 11 - Common Stock Warrants A summary of the Company’s warrant issuance activity and related information for the period ended September 30, 2021 and 2020 is as follows: SUMMARY OF WARRANT ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 368,325,486 0.015 10.30 Total outstanding at September 30, 2020 413,131,562 0.09 9.79 Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.015 10.30 Expired (5,783,189 ) $ 0.33 — Issued — — — Total outstanding and exercisable at September 30, 2021 407,640,783 $ 0.58 8.42 The fair value of all warrants issued are determined by using the Black-Scholes valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Black-Scholes valuation technique to value each of the warrants as of their respective issue dates are as follows: SCHEDULE OF ASSUMPTIONS FOR WARRANTS Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 years 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 years 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.04 3 years 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 years 0.65 100.64 Granted for bridge financing 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 years 0.65 96.97 The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Series D Convertible Preferred

Series D Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Series D Convertible Preferred Stock	Note 12 - Series D Convertible Preferred Stock On November 15, 2019, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company offered (i) up to 238,871 40.817 ten 14,669,757 10 years 0.75 On November 21, 2019, the Company entered into a securities purchase agreement with FWHC Holdings, LLC (“FWHC”) an accredited investor for the purchase of 146,998 0.001 For the nine months ended September 30, 2021 and 2020, the Company recorded $ 0 278,476 8 6,281,433 15,773,363 As of December 31, 2020, the Company does not have any Series D Convertible Preferred Stock outstanding (see Note 9 - “Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K).

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, “Income Taxes”. Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the difference turns around. The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowance is recorded when it is more likely than not that a tax benefit will not be realized. In determining the need for valuation allowances the Company considers projected future taxable income and the availability of tax planning strategies. From inception to September 30, 2021, the Company has incurred net losses and, therefore, has no current income tax liability. The net deferred tax asset generated by these losses is fully offset by a valuation allowance as of September 30, 2021 and December 31, 2020. Management of the Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize the full benefits of the deferred tax assets. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. There are no

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	N ote 14 - Subsequent Events The Company has evaluated subsequent events through November 11, 2021 and has determined that there have been no events that would require adjustments to or disclosure in the September 30, 2021 interim Consolidated Financial Statements other than those disclosed in this Form 10-Q. On October 14, 2021, H-Cyte, Inc. (the “Company”) entered into the Second Closing Bring Down Agreement (the “October 2021 Note Purchase Agreement”) whereby the five (5) investors who had entered into the April 2021 Note Purchase Agreement purchased new notes in the Company in the aggregate principal amount of $ 750,000 8 The Notes are convertible into shares of Common Stock at a discount of 20% of the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the April 2021 Note Purchase Agreement 437,000

Right-of-use Asset And Lease _2

Right-of-use Asset And Lease Liability (Tables)	9 Months Ended
	Sep. 30, 2021
Right-of-use Asset And Lease Liability
SCHEDULE OF COMPONENTS OF LEASE EXPENSE	The components of lease expense, which are included in other general and administrative expense, for the three and nine months ended September 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating lease expense $ 69,582 140,381 253,233 442,409
SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES	Cash paid for amounts included in the measurement of lease liabilities for the three and nine months ended September 30, 2021 and 2020, respectively, are as follows: SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating cash flows from operating leases $ 69,582 140,381 253,233 442,409
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION	Supplemental balance sheet and other information related to operating leases are as follows: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION September 30, 2021 December 31, 2020 Operating leases right-of-use assets $ 162,207 278,552 Lease liability, current portion 92,589 139,189 Lease liability, net of current portion 87,304 157,050 Total operating lease liabilities $ 179,893 296,239 Weighted average remaining lease term 1.92 2.32 Weighted average discount rate 9.96 % 10.31 %
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Future maturities of operating lease liabilities as of September 30, 2021 are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Operating leases Remainder of 2021 $ 25,584 2022 102,891 2023 69,333 Total lease payments 197,808 Total lease payments 197,808 Less: Interest 17,915 Total lease liability $ 179,893

Property And Equipment (Tables)

Property And Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment, net, consists of the following: SCHEDULE OF PROPERTY AND EQUIPMENT Useful Life September 30, 2021 December 31, 2020 Furniture and fixtures 5 7 $ 96,185 $ 231,222 Computers and software 3 7 213,660 246,323 Leasehold improvements 15 40,130 155,583 Property and equipment 349,975 633,128 Less: accumulated depreciation (309,631 ) (493,953 ) Total $ 40,344 $ 139,175

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS	Inputs used in the valuation models are as follows: SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS 2021 Grants Option value $ 0.054 to 0.056 Risk Free Rate 0.90 % to 1.37 % Expected Dividend- yield - to - Expected Volatility 173.99 % to 176.04 % Expected term (years) 5 to 7
SUMMARY OF STOCK OPTION ACTIVITY	The following is a summary of stock option activity for the nine months ended September 30, 2020 and 2021: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted - - - Expired/Cancelled (15,000 ) 1.35 - Outstanding and exercisable at September 30, 2020 410,000 $ 1.39 7.23 Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted 54,750,000 0.07 9.50 Expired/Cancelled (25,525,000 ) 0.07 - Outstanding at September 30, 2021 29,635,000 $ 0.10 9.41 Exercisable at September 30, 2021 14,801,667 $ 0.10 9.41
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED	The following is a summary of the Company’s non-vested shares for the nine months ended September 30, 2021: SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED Shares Weighted Non-vested at December 31, 2020 - - Granted 54,750,000 0.03 Vested (14,416,667 ) 0.05 Forfeited (25,500,000 ) 0.07 Non-vested at September 30, 2021 14,833,333 0.11
SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE	The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE 2021 2020 For the Nine Months Ended September 30, 2021 2020 Warrants to purchase common stock (in the money) 385,033,082 367,515,043 Series A Preferred Stock convertible to common stock 515,874,354 542,129,440 Total 900,907,436 909,644,483

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS	The following are rollforwards of the liabilities during the nine months ended September 30, 2020: SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS Derivative Liability - Warrants Balance at December 31, 2019 $ 315,855 Series D Warrant reclass from equity to liability classification 509,762 Warrants issued with modification of Horne Note 198,994 Warrants issued with April 17, 2020 financing 6,148,816 Fair value adjustments (2,986,853 ) Warrant reclassification from liability to equity classification (4,186,574 ) Balance at September 30, 2020 $ — Redemption Put Liability Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,306 Fair value adjustments (272,705 ) Balance at September 30, 2020 $ —

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Common Stock Warrants
SUMMARY OF WARRANT ACTIVITY	A summary of the Company’s warrant issuance activity and related information for the period ended September 30, 2021 and 2020 is as follows: SUMMARY OF WARRANT ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 368,325,486 0.015 10.30 Total outstanding at September 30, 2020 413,131,562 0.09 9.79 Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.015 10.30 Expired (5,783,189 ) $ 0.33 — Issued — — — Total outstanding and exercisable at September 30, 2021 407,640,783 $ 0.58 8.42
SCHEDULE OF ASSUMPTIONS FOR WARRANTS	SCHEDULE OF ASSUMPTIONS FOR WARRANTS Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 years 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 years 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.04 3 years 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 years 0.65 100.64 Granted for bridge financing 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 years 0.65 96.97

Description of the Company (Det

Description of the Company (Details Narrative)	9 Months Ended
	Sep. 30, 2021	Sep. 11, 2020
FWHC, LLC [Member]
Equity method investment, ownership percentage		61.00%
Rion LLC [Member] | Product Supply Agreement [Member]
Agreement Term	10 years

Liquidity, Going Concern and _2

Liquidity, Going Concern and Management’s Plans (Details Narrative) - USD ($)	Oct. 14, 2021	Apr. 02, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Nov. 11, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net Income (Loss) Attributable to Parent			$ 586,611	$ (3,949,879)	$ 4,052,290	$ 4,898,685
Proceeds from Convertible Debt					1,091,080
Cash and Cash Equivalents, at Carrying Value			$ 307,000		$ 307,000
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt Instrument, Face Amount	$ 750,000
Cash and Cash Equivalents, at Carrying Value							$ 644,000
Secured Convertible Note Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt Instrument, Face Amount		$ 2,575,000
Debt Instrument, Maturity Date		Mar. 31, 2022
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument Conversion Discount Price Percentage		20.00%
Secured Convertible Note Purchase Agreement [Member] | FWHC Bridge, LLC [Member] | Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Convertible Debt		$ 1,500,000
Secured Convertible Note Purchase Agreement [Member] | FWHC [Member] | Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Convertible Debt		$ 25,000
Second Closing Bring Down Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt Instrument, Face Amount	$ 750,000
Debt Instrument, Maturity Date	Mar. 31, 2022
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument Conversion Discount Price Percentage	20.00%
Second Closing Bring Down Agreement [Member] | FWHC Bridge, LLC [Member] | Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Convertible Debt	$ 437,000
Second Closing Bring Down Agreement [Member] | FWHC [Member] | Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Convertible Debt	$ 7,500

SCHEDULE OF COMPONENTS OF LEASE

SCHEDULE OF COMPONENTS OF LEASE EXPENSE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Right-of-use Asset And Lease Liability
Operating lease expense	$ 69,582	$ 140,381	$ 253,233	$ 442,409

SCHEDULE OF CASH PAID FOR AMOUN

SCHEDULE OF CASH PAID FOR AMOUNTS INCLUDED THE MEASUREMENT OF LEASE LIABILITIES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Right-of-use Asset And Lease Liability
Operating cash flows from operating leases	$ 69,582	$ 140,381	$ 253,233	$ 442,409

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET AND OTHER INFORMATION (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Right-of-use Asset And Lease Liability
Operating leases right-of-use assets	$ 162,207	$ 278,552
Lease liability, current portion	92,589	139,189
Lease liability, net of current portion	87,304	157,050
Total operating lease liabilities	$ 179,893	$ 296,239
Weighted average remaining lease term	1 year 11 months 1 day	2 years 3 months 25 days
Weighted average discount rate	9.96%	10.31%

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Right-of-use Asset And Lease Liability
Remainder of 2021	$ 25,584
2022	102,891
2023	69,333
Total lease payments	197,808
Less: Interest	17,915
Total lease liability	$ 179,893	$ 296,239

Right-of-use Asset And Lease _3

Right-of-use Asset And Lease Liability (Details Narrative) - USD ($)	Apr. 02, 2021	Nov. 02, 2021	Aug. 02, 2021
Tampa, FL [Member]
Lease, description	The Company did not renew its corporate office space lease in Tampa, FL which expired on March 31, 2021. The Company leases medical clinic space in Tampa, FL, Nashville, TN, and Scottsdale, AZ. These clinic locations have various expiration dates through August 31, 2023. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. The Company entered into a twelve-month lease extension for its Tampa location beginning April 1, 2021 totaling $71,775. The Company also entered into a twelve-month lease extension for its Nashville location beginning November 1, 2021 totaling $94,500. The Dallas, TX lease expired on July 31, 2020 and the Pittsburgh, PA lease expired on October 31, 2020, neither of which were renewed as these clinic locations were permanently closed.
Short-term lease commitment, amount			$ 71,775
Nashville Tennessee [Member] | Subsequent Event [Member]
Short-term lease commitment, amount		$ 94,500

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 349,975	$ 633,128
Less: accumulated depreciation	(309,631)	(493,953)
Total	40,344	139,175
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	96,185	231,222
Computers and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 213,660	246,323
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	15 years
Property and equipment	$ 40,130	$ 155,583
Minimum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Minimum [Member] | Computers and Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Maximum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Maximum [Member] | Computers and Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

Property And Equipment (Details

Property And Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 300	$ 30,000	$ 14,000	$ 69,000
Gain (Loss) on Disposition of Property Plant Equipment	$ 0		$ 93,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Oct. 14, 2021

Apr. 02, 2021

Jan. 12, 2021

Oct. 02, 2020

Sep. 11, 2020

Jul. 28, 2020

Mar. 25, 2020

Feb. 01, 2019

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Related Party Transaction [Line Items]

Proceeds from convertible debt

$ 1,091,080

Series A Preferred Stock [Member]

Related Party Transaction [Line Items]

Conversion of stock, shares issued

117,362,143

Series A Preferred Stock [Member] | Promissory Notes from April 2020 [Member]

Related Party Transaction [Line Items]

Conversion of stock, shares issued

123,031,819

Series A Preferred Stock [Member] | April Secured Note [Member]

Related Party Transaction [Line Items]

Conversion of stock, shares issued

75,162,429

Series A Preferred Stock [Member] | Hawes Notes [Member]

Related Party Transaction [Line Items]

Conversion of stock, shares issued

35,860,079

FWHC HOLDINGS, LLC [Member]

Related Party Transaction [Line Items]

Percentage of fully diluted shares owned

61.00%

Warrants issued

273,356,676

Warrant term

10 years

Warrants exercise price, per share

$ 0.014

FWHC HOLDINGS, LLC [Member] | Series D Convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Conversion of stock, shares issued

15,518,111

Board of Directors Chairman [Member]

Related Party Transaction [Line Items]

Related party compensation

$ 5,000

$ 2,500

2,500

Mr. Raymond Monteleone [Member]

Related Party Transaction [Line Items]

Salary and Wage, Officer, Excluding Cost of Good and Service Sold

18,000

$ 18,000

53,000

$ 65,000

Oral Consulting Agreement [Member]

Related Party Transaction [Line Items]

Advisory Service Fee

$ 5,000

Professional Fees

$ 2,500

Oral Consulting Agreement [Member] | Mr. Raymond Monteleone [Member]

Related Party Transaction [Line Items]

Professional Fees

$ 5,000

Oral Consulting Agreement [Member] | Mr. Raymond Monteleone [Member]

Related Party Transaction [Line Items]

Advisory Service Fee

$ 10,000

Oral Consulting Agreement [Member] | Michael Yurkowsky [Member]

Related Party Transaction [Line Items]

Professional Fees

$ 4,167

$ 4,167

Salary and Wage, Officer, Excluding Cost of Good and Service Sold

13,000

0

38,000

Oral Consulting Agreement [Member] | Mr. William Horne [Member]

Related Party Transaction [Line Items]

Salary and Wage, Officer, Excluding Cost of Good and Service Sold

$ 13,000

$ 0

$ 29,000

Secured Convertible Note Purchase Agreement [Member]

Related Party Transaction [Line Items]

Debt principal amount

$ 2,575,000

Debt instrument, maturity date

Mar. 31, 2022

Debt instrument, interest rate

8.00%

Debt instrument conversion discount price percentage

20.00%

Secured Convertible Note Purchase Agreement [Member] | Investor [Member] | FWHC Bridge, LLC [Member]

Related Party Transaction [Line Items]

Proceeds from convertible debt

$ 1,500,000

Secured Convertible Note Purchase Agreement [Member] | Investor [Member] | FWHC [Member]

Related Party Transaction [Line Items]

Proceeds from convertible debt

$ 25,000

Second Closing Bring Down Agreement [Member]

Related Party Transaction [Line Items]

Debt principal amount

$ 750,000

Debt instrument, maturity date

Mar. 31, 2022

Debt instrument, interest rate

8.00%

Debt instrument conversion discount price percentage

20.00%

Second Closing Bring Down Agreement [Member] | Investor [Member] | FWHC Bridge, LLC [Member]

Related Party Transaction [Line Items]

Proceeds from convertible debt

$ 437,000

Second Closing Bring Down Agreement [Member] | Investor [Member] | FWHC [Member]

Related Party Transaction [Line Items]

Proceeds from convertible debt

$ 7,500

SCHEDULE OF ASSUMPTIONS USED TO

SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS (Details) - 2021 Grants [Member]	9 Months Ended
	Sep. 30, 2021$ / shares
Minimum [Member]
Option value	$ 0.054
Risk-free interest rates	0.90%
Dividend yield
Volatility	173.99%
Expected life (in years)	5 years
Maximum [Member]
Option value	$ 0.056
Risk-free interest rates	1.37%
Dividend yield
Volatility	176.04%
Expected life (in years)	7 years

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Shares Options Outstanding Beginning Balance	410,000	425,000	425,000
Weighted Average Exercise Price Outstanding Beginning Balance	$ 1.39	$ 1.38	$ 1.38
Weighted Average Remaining Term (Years) Outstanding	9 years 4 months 28 days		6 years 8 months 19 days	7 years 8 months 15 days
Number of Options Granted	54,750,000
Weighted Average Exercise Price Granted	$ 0.07	$ 0
Number of Options Expired/Cancelled	(25,525,000)	(15,000)
Weighted Average Exercise Price Expired/ Cancelled	$ 0.07	$ 1.35
Number of Shares Options Outstanding and exercisable Ending Balance		410,000
Weighted Average Exercise Price Outstanding and exercisable Ending Balance		$ 1.39
Weighted Average Remaining Term (Years) Outstanding and Exercisable		7 years 2 months 23 days
Weighted Average Remaining Term (Years) Granted	9 years 6 months
Number of Shares Options Outstanding Ending Balance	29,635,000		410,000	425,000
Weighted Average Exercise Price Outstanding Ending Balance	$ 0.10		$ 1.39	$ 1.38
Options Exercisable	14,801,667
Weighted average exercise price, Exercisable	$ 0.10
Weighted Average Remaining Term (Years) Exercisable	9 years 4 months 28 days

SUMMARY OF STOCK OPTION ACTIV_2

SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Equity [Abstract]
Non-vested Shares Outstanding, Beginning Balance | shares
Non-vested, Weighted Average Grant Date Fair Value, Outstanding Beginning Balance | $ / shares
Non-vested Shares, Granted | shares	54,750,000
Non-vested, Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 0.03
Non-vested Shares, Vested | shares	(14,416,667)
Non-vested, Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 0.05
Non-vested Shares, Forfeited | shares	(25,500,000)
Non-vested, Weighted Average Grant Date Fair Value, Forfeited | $ / shares	$ 0.07
Non-vested Shares Outstanding, Ending Balance | shares	14,833,333
Non-vested, Weighted Average Grant Date Fair Value, Outstanding Ending Balance | $ / shares	$ 0.11

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	900,907,436	909,644,483
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	385,033,082	367,515,043
Series A Preferred Stock Convertible To Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	515,874,354	542,129,440

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)

Apr. 02, 2021

Sep. 24, 2020

Jul. 28, 2020

Apr. 23, 2020

Feb. 29, 2020

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Dec. 31, 2019

Jul. 29, 2020

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock, shares authorized

1,600,000,000

1,600,000,000

1,600,000,000

1,600,000,000

Preferred stock, shares authorized

1,000,000,000

1,000,000,000

1,000,000,000

1,000,000,000

Stock options granted

54,750,000

Stock options exercise price

$ 0.07

$ 0

Stock option expiration term

10 years

Share based compensation

$ 162,359

$ 1,024,359

$ 643

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

29,635,000

29,635,000

410,000

425,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

14,416,667

Share-based Payment Arrangement, Expense

$ 1,024,359

643

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

9 years 4 months 28 days

6 years 8 months 19 days

7 years 8 months 15 days

Management fee

$ 0

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

900,907,436

909,644,483

Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.04

$ 0.04

Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

22,607,701

Stock Options [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

29,635,000

Share-based Payment Arrangement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

29,635,000

29,635,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

14,801,667

Share-based Payment Arrangement, Expense

$ 162,000

$ 1,024,000

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount

$ 574,000

$ 574,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

3 years 1 month 13 days

Directors and Officers [Member] | Secured Convertible Note Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock options granted

54,750,000

Stock options exercise price

$ 0.07

Directors and Officers [Member] | Secured Convertible Note Purchase Agreement [Member] | Immediately Vested [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock options granted

4,750,000

Chief Executive Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation

$ 205,000

Series A Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share issued price per share

$ 0.014

Preferred stock, shares authorized

800,000,000

800,000,000

800,000,000

800,000,000

Stock issued during period new issue shares

15,235,381

Conversion of Stock, Shares Converted

4,431,530

22,235,055

Common stock conversion ratio

common stock at a 1:1 ratio

Series A Preferred Stock [Member] | Outstanding Promissory Note [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued during period new issue shares

323,844,416

Principal amount and accrued interest

$ 4,483,617

Series A Preferred Stock [Member] | Purchasers [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued during period new issue shares

203,049,643

Proceeds from offering

$ 3,055,985

Series B and Series D Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock conversion shares issued

17,893,076

LilyCon Investments, LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Value of shares issued for services

$ 35,000

Share issued price per share

$ 0.32

Number of shares issued for services

109,375

Home Management LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Debt conversion of common stock shares

4,368,278

Warrant term

10 years

Debt conversion price per share

$ 0.014

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.05

Commitments & Contingencies (De

Commitments & Contingencies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and Development Expense	$ 3,285	$ 201,658	$ 3,285	$ 1,151,658
Rion Agreement [Member] | Rion LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and Development Expense		$ 202,000	$ 0	$ 1,152,000

Short-term Debt (Details Narrat

Short-term Debt (Details Narrative) - USD ($)

Aug. 17, 2021

Apr. 02, 2021

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2019

Dec. 31, 2020

Apr. 29, 2020

Apr. 09, 2020

Mar. 31, 2020

Mar. 27, 2020

Short-term Debt [Line Items]

Common stock, par value

$ 0.001

$ 0.001

$ 0.001

Proceeds from Convertible Debt

$ 1,091,080

Interest Expense

$ 50,516

$ 1,039,349

110,446

$ 1,458,521

Investor [Member]

Short-term Debt [Line Items]

Notes payable

$ 500,000

$ 500,000

Third Noteholder [Member]

Short-term Debt [Line Items]

Notes payable

$ 300,000

Fees And Penalties

85,000

Interest Payable

40,000

Debt principal amount

$ 424,615

Convertible Notes Payable Related Parties [Member]

Short-term Debt [Line Items]

Interest Expense

30,445

59,665

Convertible Notes Payable [Member]

Short-term Debt [Line Items]

Interest Expense

20,962

$ 41,080

Notes Payable [Member] | Merger [Member]

Short-term Debt [Line Items]

Debt description

The Company finalized an eighteen-month extension to March 1, 2021.

Interest Payable

$ 5,000

$ 5,000

Debt Instrument, Maturity Date

Aug. 1, 2019

Debt Instrument, Interest Rate, Stated Percentage

5.00%

5.00%

Debt Instrument, Periodic Payment, Principal

$ 5,800

Promissory Notes [Member]

Short-term Debt [Line Items]

Notes payable

$ 67,000

New Principal Amount [Member] | Investor [Member]

Short-term Debt [Line Items]

Notes payable

$ 1,000,000

Securities Purchase Agreement [Member] | Accredited Investors [Member]

Short-term Debt [Line Items]

Number of common stock shares sold, value

$ 750,000

Sale of stock price per share

$ 50,000

$ 50,000

Debt description

Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40.

Conversion of common stock, percentage

12.00%

Common stock, par value

0.001

$ 0.001

Market value of common stock

$ 0.40

$ 0.40

Warrant term

3 years

3 years

Debt Conversion, Converted Instrument, Amount

$ 100,000

Redeemed Convertible Notes Value

$ 350,000

Secured Convertible Note Purchase Agreement [Member]

Short-term Debt [Line Items]

Debt principal amount

$ 2,575,000

Debt Instrument, Maturity Date

Mar. 31, 2022

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt instrument conversion discount price percentage

20.00%

Secured Convertible Note Purchase Agreement [Member] | FWHC Bridge, LLC [Member] | Investor [Member]

Short-term Debt [Line Items]

Proceeds from Convertible Debt

$ 1,500,000

Secured Convertible Note Purchase Agreement [Member] | FWHC [Member] | Investor [Member]

Short-term Debt [Line Items]

Proceeds from Convertible Debt

$ 25,000

Payroll Protection Program [Member]

Short-term Debt [Line Items]

Debt principal amount

$ 689,974

$ 809,082

Debt Instrument, Periodic Payment, Principal

$ 105,878

Interest Expense, Debt

$ 8,847

Debt Instrument, Periodic Payment, Interest

$ 405

SCHEDULE OF FAIR VALUE, LIABILI

SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
Derivative Liability- Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance, Derivative Liability- Warrants	$ 315,855
Series D Warrant reclass from equity to liability	509,762
Warrants issued with modification of Horne Note	198,994
Warrants issued with April 17, 2020 financing	6,148,816
Fair value adjustments	(2,986,853)
Warrant reclassification from liability equity classification	(4,186,574)
Ending balance, Derivative Liability- Warrants
Redemption Put Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance. Redemption Put Liability	267,399
Issuance of Series D Convertible Preferred Stock	5,306
Fair value adjustments	(272,705)
Ending balance

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative)	Sep. 11, 2020USD ($)$ / shares	Apr. 23, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of the derivative liability				$ 0		$ 0	$ 316,000
Proceeds from Issuance of Warrants						3,842,695
Fair value of warrants					$ 73,000
Redemption put liability description					The fair market value of the redemption put liability at inception
Fair value of redemption put						614,000
Other Operating Income (Expense) [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Remeasured Value Change In Fair Value Of Derivative			$ 5,869,102		$ 2,986,853
Other Operating Income (Expense) [Member] | Redemption Put Liability [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Remeasured Value Change In Fair Value Of Derivative				$ 98,000		$ 273,000
Home Management LLC [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants exercise price, per share | $ / shares		$ 0.05
Warrant term		10 years
Fair value of warrants		$ 199,000
Number of shares issued on conversion | shares		4,368,278
Measurement Input, Price Volatility [Member] | Home Management LLC [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	1.03	1.01
Measurement Input, Risk Free Interest Rate [Member] | Home Management LLC [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.0067	0.0065
Measurement Input, Exercise Price [Member] | Home Management LLC [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input		0.014
Securities Purchase Agreement [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
[custom:RedemptionPutLiability-0]			0		0		$ 267,000
Series B Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of the derivative liability			$ 317,000		317,000
Warrants exercise price, per share | $ / shares	$ 0.014
Warrants measurement input	0.027
Warrant term	1 year 3 months 29 days
Fair value of warrants	$ 73,805				$ 75,000
Warrants to purchase common stock | shares			403,125		403,125
Warrant description					In conjunction with the Series D Preferred financing (See Note 12), the Company offered the Series B warrant holders the option to exchange their warrants on the basis of 1 warrant for 0.40 common shares.
Warrants | shares			1,007,813		1,007,813
Series B Warrants [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	2.60
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.0013
Series B Warrants [Member] | April 2020 Offering [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of the derivative liability			$ 75,000		$ 75,000
Series D Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants exercise price, per share | $ / shares	$ 0.014		$ 0.75		$ 0.75
Warrants measurement input	0.00027
Warrant term	9 years 2 months 12 days
Fair value of warrants	$ 337,400
Warrants to purchase common stock | shares			14,669,757		14,669,757
Series D Warrants [Member] | Home Management LLC [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input		0.027
Warrant term		10 years
Fair value of warrants	$ 107,123
Series D Warrants [Member] | Fair Value Before and After Modification [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of the derivative liability			$ 510,000		$ 510,000
Series D Warrants [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	1.11
Series D Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.0067
Series D Warrants [Member] | Measurement Input, Exercise Price [Member] | Home Management LLC [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.014
April Bridge Loan and Converted Advance Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of warrants	$ 3,668,247				$ 6,149,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.027
Warrant term	10 years		10 years		10 years
Warrant description					The April 2020 Offering entitled the investors to warrants with the right to purchase up to 100% of the aggregate number of shares of Common Stock into which the Purchaser’s Note may ultimately be converted. The Company also received a $1,000,000 advance which was converted into a Converted Advance Note and Converted Advance Warrants in April 2020. The Converted Advance Warrants entitle the holder to purchase up to 200% of the aggregate number of shares of Common Stock into which the Converted Advanced Note may ultimately be converted.
Proceeds from Issuance of Warrants					$ 2,842,695
[custom:AdvanceNotePayable-0]			$ 1,000,000		1,000,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Exercise of Purchaser Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of warrants	$ 212,821,929				$ 3,279,000
Number of shares issuable upon exercise of warrants, shares | shares					203,050,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Converted Advance Warrants [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Fair value of warrants	$ 150,324,857				$ 2,869,000
Number of shares issuable upon exercise of warrants, shares | shares					142,857,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Price Volatility [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	1.06		1.03		1.03
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.0067		0.0065		0.0065
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Exercise Price [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input	0.014		0.014		0.014
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Trading Market [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants exercise price, per share | $ / shares			$ 0.05		$ 0.05

SUMMARY OF WARRANT ACTIVITY (De

SUMMARY OF WARRANT ACTIVITY (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Common Stock Warrants
Number of Shares, Warrants Outstanding and Exercisable, Beginning	413,423,972	44,806,076
Weighted Average Exercise Price Outstanding and Exercisable, Beggining
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable, Beginning	10 years 3 months 18 days	4 years 7 months 2 days
Number of Shares, Warrants Issued	0	368,325,486
Weighted Average Exercise Price Warrants Issued	$ 0	$ 0.015
Weighted Average Exercise Price Warrants Issued		10 years 3 months 18 days
Number of Shares, Warrants Outstanding and Exercisable, Ending	407,640,783	413,131,562
Weighted Average Exercise Price Outstanding and Exercisable, Ending	$ 0.58	$ 0.09
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable, Ending		9 years 9 months 14 days
Weighted Average Exercise Price Outstanding and Exercisable, Beggining	$ 0.015	$ 0.78
Number of Shares, Warrants Expired	(5,783,189)
Weighted Average Exercise Price Warrants Expired	$ 0.33

SCHEDULE OF ASSUMPTIONS FOR WAR

SCHEDULE OF ASSUMPTIONS FOR WARRANTS (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member]
Short-term Debt [Line Items]
Number of Warrants | shares	244,996
H-CYTE Stock Price	$ 0.15
Warrants exercise price, per share	0.75
Warrant Grant Date Fair Value	$ 0.13
Life of Warrant	10 years
Granted for Bridge Financing 04/08/2020 [Member]
Short-term Debt [Line Items]
Number of Warrants | shares	296,875
H-CYTE Stock Price	$ 0.05
Warrants exercise price, per share	0.40
Warrant Grant Date Fair Value	$ 0.04
Life of Warrant	3 years
Short Term Note, Related Party Conversion 04/17/2020 [Member]
Short-term Debt [Line Items]
Number of Warrants | shares	4,368,278
H-CYTE Stock Price	$ 0.05
Warrants exercise price, per share	0.014
Warrant Grant Date Fair Value	$ 0.05
Life of Warrant	10 years
Granted for Bridge Financing 04/17/2020 [Member]
Short-term Debt [Line Items]
Number of Warrants | shares	364,439,176
H-CYTE Stock Price	$ 0.05
Warrants exercise price, per share	0.014
Warrant Grant Date Fair Value	$ 0.017
Life of Warrant	10 years
Measurement Input, Risk Free Interest Rate [Member] | Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	0.0184
Measurement Input, Risk Free Interest Rate [Member] | Granted for Bridge Financing 04/08/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	0.0034
Measurement Input, Risk Free Interest Rate [Member] | Short Term Note, Related Party Conversion 04/17/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	0.0065
Measurement Input, Risk Free Interest Rate [Member] | Granted for Bridge Financing 04/17/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	0.0065
Measurement Input, Price Volatility [Member] | Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	1.4430
Measurement Input, Price Volatility [Member] | Granted for Bridge Financing 04/08/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	1.3182
Measurement Input, Price Volatility [Member] | Short Term Note, Related Party Conversion 04/17/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	1.0064
Measurement Input, Price Volatility [Member] | Granted for Bridge Financing 04/17/2020 [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	0.9697
Short-term Note Related Party 1/13/2020 [Member]
Short-term Debt [Line Items]
Number of Warrants | shares	268,571
H-CYTE Stock Price	$ 0.12
Warrants exercise price, per share	0.75
Warrant Grant Date Fair Value	$ 0.07
Life of Warrant	3 years
Short-term Note Related Party 1/13/2020 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	0.0160
Short-term Note Related Party 1/13/2020 [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Warrant Input, Percentage	1.4576

Series D Convertible Preferre_2

Series D Convertible Preferred Stock (Details Narrative) - USD ($)	Jul. 28, 2020	Nov. 21, 2019	Nov. 15, 2019	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Sep. 11, 2020
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Stock Issued During Period, Value, New Issues					$ 218,414
FWHC HOLDINGS, LLC [Member]
Class of Stock [Line Items]
Warrant term							10 years
Warrants exercise price, per share							$ 0.014
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Dividends, Preferred Stock				$ 0	$ 278,476
Preferred Stock, Dividend Rate, Percentage					8.00%
Stock Issued During Period, Value, New Issues					$ 6,281,433
Debt Conversion, Converted Instrument, Shares Issued	15,773,363
Securities Purchase Agreement [Member] | FWHC HOLDINGS, LLC [Member]
Class of Stock [Line Items]
Stock issued during period new issue shares		146,998
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Share issued price per share			$ 40.817
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Maximum [Member] | Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued during period new issue shares			238,871
Securities Purchase Agreement [Member] | Accredite Investors [Member] | Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of warrants to purchase common stock			14,669,757
Warrant term			10 years
Warrants exercise price, per share			$ 0.75

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax positions	$ 0	$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Oct. 14, 2021USD ($)
Subsequent Event [Line Items]
Debt instrument face amount	$ 750,000
Debt instrument bearing interest percentage	8.00%
Debt instrument description	The Notes are convertible into shares of Common Stock at a discount of 20% of the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the April 2021 Note Purchase Agreement
October Two Thousand And Twenty One Purchase Agreement [Member] | FWHC Bridge, LLC [Member]
Subsequent Event [Line Items]
Debt instrument face amount	$ 437,000